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The chemotactic response of leukocytes is a behavioral phenomenon that is the end 
result  of a  complex series  of integrated  biochemical  events.  Chemotaxis  appears  to 
require recognition by cells of chemical gradients  in their surrounding environment, 
transduction  of this  information  from  the  exterior  to  the  interior  of the  cell,  and 
translation  of the  information  into  directed  cell  movement  through  alterations  in 
cellular metabolism and rearrangement ofcytoskeletal elements (1-6). It has recently 
been  established  that  leukocytes  contain  specific  cell-surface  receptors  for  certain 
chemoattractants  and  it  has  been  surmised  that  these  receptors  are  important  in 
initiating the'biological effects of the chemotactic factors (1-3). 
Recent studies have demonstrated that a  human monocyte-like cell line, U937  (7- 
10),  can  be stimulated  to differentiate  into macrophages  in  vitro in  the presence of 
culture supernates obtained from stimulated,  but not unstimulated,  lymphocytes (9). 
We have shown that these cells in the unactivated state lack chemotactic responses to 
three  defined  chemoattractants,  but  develop  a  directed  migratory  response  after 
activation of the cells with lymphokines (11). We now report that the development of 
two  N-formylated-peptide-induced  biological  responses,  chemotaxis,  and  lysosomal 
enzyme release,  (12,  13)  during differentiation  of U937 cells are associated  with  the 
simultaneous appearance on the cells of specific surface receptors for chemoattractants. 
Materials  and Methods 
Chemicals.  N-Formyl-L-methionyl-L-leueyl-L-phenylalanine (fMet-Leu-Phe) a and N-formyl- 
norleucyl-leucyl-phenylalanine  (fNle-Leu-Phe)  were  obtained  from  Peninsula  Laboratories, 
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Abbremattons used in this p  a~.er: EC6o, one-half maximal  inhibition  of binding,  fMet-Leu, N-formyl- 
rnethionyl-leucine; fMet-Leu-[ H]Phe, tritiated  N-forrnyl-rnethionyl-leucyl-phenylalanine;  fMet-Leu-Phe, 
N-formyl-L-methionyl-L-leucyl-L-phenylalanine; fMet-Met-Met;  N-forrnyl-methionyl-rnnethlonyl-rnethlo- 
nine; fN[e-Leu-Phe,  N-formyl-norleucyl-leucyl-phenylalanine;  incubation buffer, phosphate-buffered saline 
that contained 1.7 mM KH2PO4, 8 mM Na2HPO4, 0.117 rnM NaCI, 0.15 mM CaCI~, and 0.5 mM MgCI2, 
pH 7.2; LDH, lactic acid dehydrogenase; RPMI-FCS, RPMI-1640 medium that contained  10% (vol/vol) 
heat-inactivated (30 rnin at 56°C) fetal calf serum. 
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Inc.,  San  Carlos,  Calif.  Noformyl-methionyl-methionyl-methionine (fMet-Met-Met)  and  N- 
formyl-methionyl-leucine (fMet-Leu) were ~urchased from Andrulis Research Corp., Bethesda, 
Md.  Tritiated  fMet-Leu-Phe  (fMet-Leu-[ H]Phe)  (57  Ci/mmoi)  was  from  New  England 
Nuclear, Boston, Mass., and Hepes was obtained from Calbiochem-Behring Corp., American 
Hoechst  Corp.,  San  Diego,  Calif.  Phenolphthalein  glucuronic  acid  and  dried  Micrococcus 
lysodeikticus were  purchased  from  Sigma  Chemical  Co.,  St.  Louis,  Mo.  The  chemotactic 
stimulants zymosan, activated human serum (14), and lymphocyte-derived chemotactic factor 
(15, 16) were prepared as previously described. 
Cell preparations.  U937 cells were grown in RPMI-1640 medium that contained  10% (vol/ 
vol)  heat-inactivated  (30  min  at  56"C)  fetal  calf serum  (RPMI-FCS)  (B  &  B  Research 
Laboratories, Baltimore, Md.). The cells were maintained at 37"C and passaged as previously 
described (9). Before use in the functional and binding assays,  the cells were washed twice in 
phosphate-buffered saline that contained 1.7 mM KHzPO4, 8 mM NazHPO4, 0.117 M  NaCI, 
0.15 mM CaClz, and 0.5 mM MgCI2, pH 7.2 (incubation buffer). 
Preparation ofLymphokine-ri'ch Supernates.  Human mononuclear leukocytes obtained by sepa- 
ration of whole human blood on Fieoll-  (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., 
Piscataway, N. J.) Hypaque (Winthrop Laboratories, New York) gradients were incubated in 
RPMI-FCS  for 48  h  at  37°C in  the presence of 1 btg/ml  phytohemagglutinin  (Burroughs- 
Wellcome Corp., Research Triangle Park,  N. C.). After incubation,  the cell  supernates were 
collected after centrifugation and stored at -200C until used. 
Chemotaxis Assay.  Chemotaxis was assayed in modified Boyden chambers using a  5.0-#m 
polycarbonate filter (Nuclepore Corp., Pleasanton, Calif.) (15, 17). Chemotactic activity of the 
various stimulants  was measured  as the mean number of migrating cells  per oil-immersion 
microscopic  field  (magnification:  X  1,000)  in  triplicate  samples  and  is  expressed  as  the 
percentage of the maximal response obtained with each chemoattractant. 
fMet-Leu-[3H]Phe-binding Assay.  Five million U937 cells were incubated with the indicated 
concentration of fMet-Leu-[SH]Phe in a total voi of 0.15 ml in the presence and absence of 10 
laM unlabeled fMet-Leu-Pbe. After the appropriate incubation time at 23°C, t;he cell suspen- 
sions were rapidly filtered onto glass fiber discs (Whatman GF/C; Whatman, Inc., Clifton, N. 
J.)  (1), which were then  washed with  24  ml  of ice-cold incubation  buffer.  The  filters  were 
placed into scintillation vials with  10 ml of Aquasol (Imperial Chemical Industries, Inc., Los 
Angeles, Calif.)  and the radioactivity was measured by liquid scintillation spectroscopy. Specific 
binding is defined as total binding minus nonspecific binding which is the amount of fMet- 
Leu-[ H]Phe bound in the presence of 10 #M unlabeled fMet-Leu-Phe (18,  19). 
Assay of Lysosomal Enzyme Release,  U937 cells (5 ×  10  n eells/ml) were suspended in phosphate- 
buffered  saline  that  contained  .138  M  NaCI,  2.7  mM  KCI,  8.1  mM  Na2HPO4,  1.5  mM 
KH2PO4, 0.6 mM CaCI~, and 1.0 mM MgCI2, pH 7.4 (20) in the presence and absence of 10  -s 
M  cytochalasin B. After incubation for 15 min. at  37°C, ehemotactic factors or buffer alone 
were added to the cells and the reaction was allowed to proceed for 15 rain at 37°C. The tubes 
were then immersed in an ice bath and centrifuged. The supernates were assayed for lysozyme 
(21),/~-glucuronidase (22), and lactic acid dehydrogenase (LDH) (23). 
Results 
Kinetics  of the Development of Chemotaxis and Lysosomal Enzyme  Secretion in  U937 Cells 
Treated with Lymphokines.  Our previous studies demonstrated  that  U937 cells, when 
incubated with lymphokines, developed a chemotactic response to fMet-Leu-Phe (11). 
To  determine  whether  stimulated  U937  cells  developed  another  chemoattractant- 
induced  function,  lysosomal  enzyme  secretion  (13),  the  cells  were  incubated  with 
RPMI-FCS that  contained  5%  (vol/vol)  lymphokine supernates  for 24, 48, or 72 h, 
washed, and tested for their ability to release B-glucuronidase and lysozyme in response 
to  10  btM  fMet-Leu-Phe  (Fig.  1 A).  These  cells  were  also  studied  for  chemotactic 
responsiveness to the same agent (Fig.  1 B). Unactivated U937 cells released small but 
significant amounts of B-glucuronidase and lysozyme in the presence of peptide  and 
10 ~M cytochalasin B  (Fig.  1A). When the cells were stimulated  with lymphokines, M.  C.  PIKE, D.  G.  FISCHER,  H.  S.  KOREN,  AND  R.  SNYDERMAN 
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Fro.  1.  Development of lysosomal  enzyme secretion  (A)  and  chemotactic  responsiveness  (B) 
induced by fMet-Leu-Phe in stimulated U937 cells. U937 cells were incubated in 5% lymphokine 
supernates  (vol/vol)  for 24, 48 or 72 h, washed,  and resuspended  in the appropriate buffer for 
chemotaxis or secretion assays. Lysozyme and/~-glucuronidase  activities were measured in supernates 
of cells (5 ×  10S/ml) that had been incubated with 10~aM cytochalasin  B and 10 jaM fMet-Leu-Phe, 
and are expressed  as the percentage  of total enzyme released.  Enzyme release obtained in the 
presence of cytochalasin  B alone was subtracted from the values obtained in the presence of the 
peptide,  and each point represents the mean of duplicate determinations. The actual amounts of 
lysozyme and/3-glucuronidase released  at 0, 24, 48, and 72 h were 0.2, 0.5, 0.7, and  1.2/~g/ml 
equivalent  lysozyme  units,  respectively,  and  1.0, 5.9, 12.5, and  26.5 nmol  phenolphthalein 
formed/h per 10  cells, respectively. Chemotaxis is expressed as the percent of maximal chemotactic 
activity of cells migrating completely  through the filter  in response  to 50 nM fMet-Leu-Phe in 
triplicate samples. The migration of cells in response to Gey's buffered  salt solution alone were 
subtracted from  values obtained in the presence of fMet-Leu-Phe.  (O) //-glucuronidase and (C)) 
lysozyme released; (&) chemotactic  response. 
the  release  of both  enzymes increased  markedly with  increased  time of incubation. 
Maximal release of lysozyme occurred in cells that had been incubated for 48 h  with 
lymphokines, and was 41% of the total lysozyme content, fl-glucuronidase release was 
maximal after  72  h,  and was  42% of the  total  amount  of this enzyme. The  cellular 
content of both enzymes increased with increasing time of stimulation with lympho- 
kines. Lysozyme content at 0, 24, 48, and 72 h  after stimulation was 0.9 ±  0.1, 0.8 + 
0.03,  1.3  +  0.1,  and  1.6  4- 0.06 ~g equivalent lysozyme units/106 cells, respectively, 
and values for total fl-glucuronidase content were 48.6 ±  1.3, 50.8 ±  0.9, 99.2 ±  7.2, 
126.6 4- 5.0/zmol phenolphthalein formed/h per  106 cells, respectively. The release of 
lysosomal enzymes in response to fMet-Leu-Phe was not a  result of cell death because 
there was no observable release of the cytoplasmic enzyme, LDH. The appearance of 
lysosomal enzyme secretion  in U937  cells  paralleled  the  appearance  of chemotactic 
responsiveness to 50 nM  fMet-Leu-Phe (Fig.  1 B). 
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by Lymphokine-rich Supernates.  To determine whether the development of fMet-Leu- 
Phe induced biologic functions depended on  the appearance of a  specific cellular 
binding site for the formylated peptide chemotactic factors, U937 cells were grown in 
medium alone or in medium that contained 5% (vol/vol) lymphokines for 24, 48, or 
72 h. The cells were then washed and tested for the ability to specifically bind fMet- 
Leu-[aH]Phe. U937 cells grown in the presence of medium alone did not specifically 
bind fMet-Leu-[aH]Phe in concentrations ranging from 5 to 40 nM  (Fig. 2). When 
cells  were  incubated  in  the  presence  of 5%  lymphokine-rich supernate  for  24  h, 
however,  specific  saturable  binding  of  fMet-Leu-[aH]Phe  was  detected  (Fig.  2). 
Exposure of U937 cells to lymphokines for longer periods of time in culture resulted 
in a  correspondingly increased amount of specific fMet-Leu-[nH]Phe binding.  The 
numbers of sites per cell calculated using Scatchard analysis (24) were 4,505 ±  1,138, 
22,150  ±  4,030,  and 37,200  ±  8,000  (n =  2)  for cells activated for 24, 48, and 72 h, 
respectively. The dissociation constants (KD) for the interaction of fMet-Leu-[nH]Phe 
with the receptor on U937 cells were approximately the same regardless of the time 
of activation, and ranged between 15 and 30 nM. 
Kinetics and Reversibility of fMet-Leu-[3H]Phe  Binding  to Activated  U937 Cells.  U937 
cells that had been grown for 48 h  in the presence of 5% (vol/vol) lymphokine-rich 
supernates were incubated with  10 nM fMet-Leu-[nH]Phe, and specific binding was 
assayed at various times after incubation at 23°C (Fig. 3). The binding of fMet-Leu- 
[aH]Phe reached equilibrium by 45 min; the time required to reach one-half equili- 
bration (tl/2) was ~ 16 min at 25°C. To determine whether the binding of fMet-Leu- 
[aH]Phe was reversible, a large excess (10 ~M) of unlabeled fMet-Leu-Phe was added 
to an equilibrated mixture of the labeled ligand and U937 cells, and specific binding 
was assayed after various times thereafter (Fig. 3). The bound fMet-Leu-[nH]Phe was 
rapidly  displaced  by  the  addition  of the  unlabeled  peptide;  >50%  of the  bound 
peptide was displaced by 5 rain after the addition of unlabeled fMet-Leu-Phe. 
Specificity  of the  N-Formylated  Peptide  Receptor on  U937  Cells.  Experiments  were 
performed to determine whether the binding sites for fMet-Leu-[aH]Phe on stimulated 
U937  cells  possessed  the  specificity expected  of a  receptor  for  the  N-formylated 
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FIG.  2.  Development of a specific binding site for fMet-Leu-[3H]Phe on the surface of U937 cells 
as a  function of time. I3'937 cells were incubated in 5% lymphokine supernates for 24, 48, or 72 h, 
washed, and resuspended in incubation buffer. Five million cells were incubated with the indicated 
concentrations of fMet-Leu-[3H]Phe in the presence and absence of 10 #M unlabeled peptide for  1 
h  at  23°C,  filtered,  and the specific binding was determined.  Each  point  represents the mean of 
duplicate determinations from two separate experiments. U937 cells activated for (*) 0 h; (O)  24 h; 
((3) 48 h; and (A)  72 h. M.  C.  PIKE, D.  G.  FISCHER,  H.  S.  KOREN,  AND  R.  SNYDERMAN  35 
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Ftc.  3.  Time-course and reversal of fMet-Leu-[aH]Phe  binding to activated U937 cells. Cells were 
cultured for 48 h in the presence of 5% lymphokines (vol/vol), washed, and incubated with 10 nM 
fMet-Leu-[aH]Phe at 23°C for various periods of time, after which specific binding was calculated 
(0). A large excess (10/aM)  of unlabeled fMet-Leu-Phe was added to some mixtures (C)) after 45 
rain at 23"C and the specific binding of the ligand was determined at subsequent time intervals. 
Each point represents the mean of duplicate determinations. 
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Fie.  4.  Specificity of the chemotactic response of activated U937 cells to a series of N-formylated 
peptides. U937 cells cultured for 48 h in lymphokines were tested for chemotactic responsiveness to 
the indicated concentrations of peptides.  Chemotactic  activity was  determined as the  average 
number of cells migrating completely through the filter in 20 microscopic fields and is expressed as 
the percent of the maximal response obtained for each peptide. The maximal responses were (cells/ 
microscopic field, magnification: ×  1,000); (O)  fMet-Leu-Phe (57.7); (*)  fMet-Met-Met  (206.0); 
(A)  fNle-Leu-Pbe  (81.7); and  (O)  fMet-Leu  (160.0).  Results  given  are  the  mean of triplicate 
determinations. 
peptides.  U937  cells were  cultured  for  48  h  with  lymphokines and  tested  for  their 
ability to respond chemotactically to various concentrations of a series of N-formylated 
peptides.  Fig. 4  indicates that  the peptides,  fMet-Leu-Phe,  fNle-Leu-Phe, and fMet- 
Met-Met  were  approximately  equipotent  for  eliciting  a  chemotactic  response  in 
stimulated U937 cells, whereas the peptide fMet-Leu was less potent by approximately 
three orders of magnitude. These results are in good agreement with the potencies of 
these same peptides for producing a  chemotactic response in guinea pig macrophages 
(25). 
The same peptides were also tested for their relative potency for inducing lysosomal 
enzyme secretion by U937 cells. Cytochalasin B-treated cells, which had been stimu- 
lated with  lymphokines for 48 h, were  incubated with  various concentrations of the 
peptides  for  15  min  at  37°C,  after  which  time  the  amount  of  lysozyme  and  /~- 36  CHEMOTACTIC-PEPTIDE  RECEPTORS  IN  A  MONOCYTE  CELL  LINE 
glucuronidase activities in the supernate fluid was measured. The peptides exhibited 
the same order of potency for releasing lysozyme activity from the U937 cells (Fig. 5) 
as was noted for the induction of the chemotactic response, fMet-Leu-Phe -  fNle- 
Leu-Phe  =  fMet-Met-Met  >  fMet-Leu.  Identical  results  were  obtained  when  fl- 
glucuronidase activity was  measured  in  the cell supernates.  The  concentrations of 
peptides necessary to induce lysosomal enzyme release were 10-15 times greater than 
the  concentrations  necessary  for  eliciting a  chemotactic  response,  a  phenomenon 
which has also been noted in studies using rabbit polymorphonuclear leukocytes (13). 
If the binding of fMet-Leu-[aH]Phe to activated U937 cells is in fact representative 
of binding to a site that mediates the biological responses of these cells to N-formylated 
peptides, then the affinity of various peptides for the binding site should reflect their 
biological potency. The ability of the various peptides to compete with fMet-Leu- 
[aH]Phe for cellular binding was therefore tested. Each of the peptides was added in 
several concentrations to incubation mixtures containing fMet-Leu-[aH]Phe (10 nM) 
and stimulated U937 cells, and the percent of fMet-Leu-[3H]Phe binding inhibited in 
the presence of the unlabeled peptides was determined (Fig. 6). The order of potencies 
of these peptides in competing for tMet-Leu-[aH]Phe-binding sites exactly paralleled 
their order of potencies for producing chemotactic responses and lysosomal enzyme 
release. Excellent correlation between the doses of peptides which produced one-half 
maximal inhibition of binding (EC~0) and  half maximal lysosomai enzyme release 
(r =  0.99)  and chemotaxis (r =  0.99)  were obtained. 
Discussion 
The monocyte-like cell line U937, established from a human histiocytic lymphoma 
(7) was adapted to rapid growth in vitro (9). U937 cells have low levels of antibody- 
dependent cellular cytotoxicity, immune phagocytic activity, and Fc receptors in the 
unstimulated state, but develop increased killer and phagocytic activity as well as Fc 
receptors upon incubation with lymphokines (9). Our studies demonstrate that other 
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Fro.  5.  Specificity of lysosomal enzyme release  of activated U937 cells to a series of N-formylated 
peptides. U937 cells cultured  for 48 h in  lymphokines were tested for the release  of [ysozyme in 
response to various concentrations of the indicated peptides as described in Materials and Methods. 
Enzyme activity is expressed as the percent of maximal lysozyme release obtained for each peptide, 
and each point represents the mean of duplicate determinations. See legend to Fig. 4. M.  C.  PIKE, D.  G.  FISCHER, H. S.  KOREN, AND R.  SNYDERMAN  37 
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Fzo. 6.  Inhibition of fMet-Leu-[aH]Phe  binding to activated U937 cells by a series  of N-formylated 
peptides. U937 cells cultured for 48 h with lymphokines  were washed and incubated at 23°C with 
10 nM fMet-Leu-[3H]Phe  in the presence or absence of the indicated concentration of peptide for 
1 h, after which the specific binding was calculated. Results are expressed as percent inhibition of 
fMet-Leu-[3H]Phe binding, and each point represents the mean of duplicate incubation conditions. 
See legend to Fig. 4. 
important  functions of leukocytes, chemotaxis and  lysosomal enzyme secretion,  de- 
velop in the U937 cells upon differentiation in the presence of lymphokines. Further- 
more, the appearance of these biological functions is correlated with the development 
of specific cell-surface receptors for an agent which induces these same functions. The 
incubation ofU937 cells with culture supernates from stimulated lymphocytes induces 
the appearance of specific cell-surface receptors for N-formylated peptides which are 
potent  chemoattractants  and  secretogogues  for  leukocytes.  Cells  incubated  with 
lymphocyte supernates  for increasing periods of time developed increasing numbers 
of receptors. The numbers of sites per cell, assuming cellular homogeneity were 4,505 
+  1,138,  22,150  ±  4,030, and 37,200 ±  8,000  for cells stimulated for 24, 48, or 72 h, 
respectively. The development of greater chemotactic responsiveness in the U937 cells 
paralleled  the  appearance  of  larger  numbers  of  receptors  for  the  N-formylated 
peptides. The affinity of the receptor did not appear to differ during the various times 
after stimulation with lymphokines and consistently ranged between  15 and 30 nM. 
The binding of fMet-Leu-[aH]Phe to the receptor sites was rapid and reversible in the 
presence of a large excess of unlabeled peptide. 
Although  we could  detect  no consistent  specific binding of fMet-Leu-[3H]Phe or 
chemotactic activity by unstimulated cells, some release of lysozyme and fl-glucuron- 
idase was detected when these cells were exposed to high doses (I0/.tM) of fMet-Leu- 
Phe. The unactivated U937 cells could contain small numbers of low-affinity binding 
sites for fMet-Leu-Phe on their surfaces. The radioligand-binding assay is insufficient 
to  detect  low-affinity  binding  sites  because  the  high  concentrations  of fMet-Leu- 
[3H]Phe needed for such analyses results in large amounts of nonspecifie binding to 
the  cells.  The release of enzymes in  unstimulated  cells cannot  be attributed  to  an 
increase in receptor number as a result of incubation with cytochalasin B because this 
compound did not affect the amount of fMet-Leu-[aH]Phe bound to these cells. 
The  affinity of a  series  of N-formylated peptides  for the  receptor on  stimulated 
U937  cells  paralleled  the  activity  of the  peptides  for  producing  chemotaxis  and 
lysosomal enzyme release, thereby demonstrating the specificity of the receptor as well 
as its biological relevance. The correlation coefficients (r) calculated from the ECs0 for 38  CHEMOTACTIC-PEPTIDE  RECEPTORS  IN A MONOCYTE  CELL  LINE 
inhibition of fMet-Leu-[3H]Phe binding and the ECs0 for chemotaxis and lysosomal 
enzyme secretion were both 0.99. The specificity of the receptor on activated U937 
cells was  similar  to  that  found on  guinea  pig  macrophages  (25,  26),  but  may be 
slightly  different  from  that  present  on  human  peripheral  blood  monocytes.  The 
potencies of fMet-Met-Met and  fNle-Leu-Phe for human  monocyte chemotaxis are 
less  than  that  of  fMet-Leu-Phe  (M.  C.  Pike  and  R.  Snyderman.  Unpublished 
observation.), whereas the potencies of all three peptides for chemotaxis by stimulated 
U937 cells are identical. The affinity of fMet-Leu-Phe for the receptor on stimulated 
U937 cells (15-30 nM) is similar to the affinity of fMet-Leu-Phe for the receptors on 
guinea pig maerophages (8-12 nM) and human polymorphonuclear leukocytes (10- 
15 nM)  (1).  The affinity of fMet-Leu-Phe for human  monocytes has  not  yet been 
determined by direct binding assay. 
The  availability  of a  human  monocyte-like  cell  line  that,  in  one  state,  lacks 
detectable amounts of the N-formylated chemotactic peptide receptor, but possesses 
it in another state, will greatly facilitate both the biochemical characterization of the 
receptor and provide information concerning the regulation of the biological activities 
of leukocytes during differentiation processes. This cell line should also be useful for 
further delineating the transductional events that  occur after receptor binding and 
that are required for chemotaxis and lysosomal enzyme release. 
Summary 
A  human  monocyte-like cell line, U937, when grown in continuous culture, does 
not secrete lysosomal enzymes or migrate towards chemotactic factors. When the cells 
are stimulated  by lymphokines, however, they develop the ability both to migrate 
directionally and to secrete enzymes in response to several types of chemoattractants. 
The development, by stimulated cells, of chemotactic and secretory responses to one 
class of chemoattractants, the N-formylated peptides, is accompanied by the appear- 
ance on  the  cells of specific binding  sites  for these  substances.  Using  tritiated  N- 
formyl-methionyl-leueyl-phenylalanine (fMet-Leu-[nH]Phe) as a ligand, it was deter- 
mined  that  unstimulated  U937  cells possess  no detectable binding  sites.  However, 
after  stimulation  with  lymphocyte culture  supernates  for  24,  48,  and  72  h,  they 
developed 4,505 ±  1,138,  22,150 ±  4,030, and 37,200 :lz 8,000 sites/cell, respectively. 
The dissociation constants for the interaction of fMet-Leu-[SH]Phe with the binding 
sites were approximately the same regardless of stimulation time and ranged between 
15 and 30 nM. The binding of fMet-Leu-[3H]Phe by stimulated U937 cells was rapid 
and  readily reversed by  the  addition  of a  large  excess of unlabeled  peptide.  The 
affinity of a series of N-formylated peptides for binding to U937 cells exactly reflected 
the potency of the peptides in inducing lysosomal enzyme secretion and chemotaxis. 
The availability of a continuous human monocytic cell line that can be induced to 
express receptors for N-formylated peptides will provide a useful tool not only for the 
characterization of such receptors but also for the delineation of regulatory mecha- 
nisms involved in cellular differentiation and the chemotactic response. 
Received  for publication 3 March  1980. 
References 
1.  Williams, L. T., R. Snyderman, M. C. Pike, and R. J.  Lefkowitz.  1977. Specific  receptor 
sites for chemotactic peptides on human polymorphonuclear leukocytes.  Proc. Natl.  Acad. 
Sci.  U. S.  A. 74:1204. M.  C.  PIKE,  D.  G.  FISCHER,  H.  S.  KOREN, AND R.  SNYDERMAN  39 
2.  Aswanikumar, S., B. A. Corcoran, E. Schiffman, A. R. Day, R. J. Freer, H. J. Showell, E. 
L. Becker,  and C.  B.  Pert.  1977. Demonstration of a  receptor on rabbit  neutrophils  for 
chemotactic peptides. Biochan. Biophys. Res. Cornraun. 74:810. 
3.  Chenoweth, D. E., and T. E. Hugli.  1978. Demonstration of specific C5a receptor on intact 
polymorphonuclear leukocytes. Proc. Natl.  Acad. Sci. U. S. A. 75:3943. 
4.  Niedel, J., S. Wilkinson, and P. Cuatreeasas.  1979. Receptor-mediated uptake and degra- 
dation of t2SI-chemotactic  peptide by human neutrophils. J. Biol. Chem. 254:10700. 
5.  Gallin, J.  I., E. K. Gallin,  H. L. Malech, and  E. B. Cramer.  1978. StrUctural and  ionic 
events during leukocyte chemotaxis. In Leukocyte Chemotaxis: Methods, Physiology and 
Clinical Implications. J. I. Gallin and P. G. Quie, editors. Raven Press,  New York.  123. 
6.  Naccache, P. H., H. J. Showell, E. L. Becker, and R. I. Sha'afi. 1977. Transport of sodium, 
potassium and calcium across rabbit polymorphonuclear leukocyte membranes.J. Cell Biol. 
73:428. 
7.  Sundstrom,  C.,  and  K.  Nilsson.  1976. Establishment  and  characterization  of a  human 
histiocytic lymphoma cell line (U-937).  Int. J. Cancer. 17:565. 
8.  Lachman, L. B., J. O. Moore, and R. S. Metzger.  1978. Preparation and characterization 
of  lymphocyte-activating factor (LAF) from acute monocytic and myelomonocytic leukemia 
cells. Cell, lmmunol. 41:199. 
9.  Koren,  H.  S.,  S. J.  Anderson, and J.  W.  Larrick.  1979. In vitro activation of a  human 
macrophage-like, cell line. Nature (Lond.).  279:328. 
10.  Ralph, P., M. A. S. Moore, and K. Nilsson.  1976. Lysozyme  synthesis by established human 
and murine histiocytic cell lines.J.  Exp. Med.  143:1528. 
11.  Fischer, D. G., M. C. Pike, H. S. Koren, and R. Snyderman. Chemotactically responsive 
and non-responsive forms of a human monocyte cell line.J, lmmunol, In press. 
12.  Schiffmann, E.,  B. A. Corcoran, and S. M. Wahl.  1975. N-formyl-methionyl peptides as 
chemoattractants for leukocytes. Proc. Natl.  Acad. Sci. U. S. A. 72:1059. 
13.  Showell, H.J., R. J. Freer, S. H. Zigmond, E. Schiffmann, S. Aswanikumar, B. A. Corcoran, 
and E. L. Becker.  1976. The structure-activity relations of synthetic peptides as chemotactic 
factors and inducers of lysosomal enzyme secretion for neutrophils.J.  Exp.  Med. 143:1154. 
14.  Snyderman,  R., and  S.  E.  Mergenhagen.  1972. Characterization  of polymorphonuclear 
leukocyte chemotactic  activity  in  serums  activated  by various  inflammatory agents.  In 
Biological  Activities of Complement. D. G. Ingram, editor. S. Karger AG, Basel.  117. 
15.  Snyderman, R., L. C. Altman, M. S. Hausman, and S. E. Mergenhagen.  Human mono- 
nuclear leukocyte chemotaxis: a quantitative assay for humoral and cellular chemotactic 
factors.J. Immunol. 108:857. 
16.  Ahman, L. C., R. Snyderman, J. J. Oppenheim, and S. E. Mergenhagen.  1973. A human 
mononuclear  leukocyte chemotactic  factor:  characterization,  specificity  and  kinetics  of 
production by homologous leukocytes. J. Immunol. 110:801. 
17.  Snyderman,  R.,  and  M.  C.  Pike.  1976. Chemotaxis  of mononuclear cells.  In  In Vitro 
Methods in Cell Mediated and Tumor Immunity. B. R. Bloom and J. R. David, editors. 
Academic Press Inc., New York. 651. 
18.  Lefkowitz, R. J., L. E. Limbird, C. Mukherjee, and M. G. Caron.  1976. The/~-adrenergic 
receptor and adenylate eyelase.  Biochim. Biophys. Acta. 457:1. 
19.  Williams,  L.  T.,  and  R.  J.  Lefkowitz.  1978. Receptor  Binding  Studies  in  Adrenergie 
Pharmacology. Raven Press,  New York.  1. 
20.  Goldstein,  I.  M.,  D.  Roos,  H.  B.  Kaplan,  and  G.  Weissmann.  1975. Complement  and 
immunoglobulins stimulate  superoxide production by human leukocytes independent  of 
phagocytosis.J. Clin. Invest. 56:1155. 
21.  Shugar,  D,  1952. Measurement  of lysozyme activity and  the ultraviolet  inactivation  of 
lysozyme. Biochim. Biophys. Acta. 8:302. 
22.  Fishman, W. H., B. Springer, and R. Brunetti.  1948. Application of an improved glucu- 40  CHEMOTACTIC-PEPTIDE  RECEPTORS  IN A  MONOCYTE  CELL  LINE 
ronidase assay method to the study of human blood fl-glucuronidase. J.  Biol.  Chem. 173: 
449. 
23.  Wroblewski, F., and J. S. LaDue.  1955. Lactic dehydrogenase activity in blood. Proc. Soc. 
Exp. Biol. Med. 90:210. 
24.  Scatchard, G.  1949. The attractions of proteins for small molecular and ions. Ann.  N.  E 
Acad. Sci. 51:660. 
25.  Pike,  M.  C.,  N.  M.  Kredieh,  and  R.  Snyderman.  1979. Phospholipid  methylation  in 
macrophages is inhibited by chemotactic factors. Proc. Natl.  Acad. Sci. U. S. A. 76:2922. 
26.  Snyderman,  R.,  and  E.  Fudman.  Demonstration  of a  chemotactic  factor  receptor on 
macrophages.J. Immunol. In press. 